主要研究目的：本研究以海南科进生物制药有限公司提供的盐酸奥洛他定口崩片（规格：5mg）为受试制剂，以原研厂家協和キリン株式会社持证的盐酸奥洛他定口崩片（规格：5mg，商品名：Allelock®）为参比制剂，评价受试制剂和参比制剂在空腹及餐后条件下给药后的生物等效性。次要研究目的：观察单次口服5mg的盐酸奥洛他定口崩片受试制剂或参比制剂在健康试验参与者中的安全性。

[Translation]

Primary objective: This study evaluated the bioequivalence of olopatadine hydrochloride orally disintegrating tablets (5 mg) supplied by Hainan Kejin Biopharmaceutical Co., Ltd., and olopatadine hydrochloride orally disintegrating tablets (5 mg, trade name: Allelock®) certified by Kyowa Kirin Co., Ltd., under fasting and postprandial administration conditions. Secondary objective: To observe the safety of a single oral dose of 5 mg olopatadine hydrochloride orally disintegrating tablets (test or reference formulation) in healthy trial participants.

Start Date25 Apr 2026

Sponsor / Collaborator

Kirgen Biological Pharmaceutical(Hainan) Co., Ltd.

CTR20260022

/ RecruitingPhase 3

盐酸奥洛他定鼻喷雾剂治疗季节性过敏性鼻炎的有效性和安全性的多中心、随机、双盲、安慰剂平行对照的III期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to assess the efficacy and safety of olopatadine hydrochloride nasal spray in the treatment of seasonal allergic rhinitis.

评价盐酸奥洛他定鼻喷雾剂治疗季节性过敏性鼻炎的有效性和安全性

[Translation]

Evaluate the efficacy and safety of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.

Start Date08 Apr 2026

Sponsor / Collaborator

Yingkerui (Hengqin) Pharmaceutical Research Institute Co., Ltd.

ChiCTR2500115530

/ SuspendedPhase 4IIT

Efficacy of 0.05% Cyclosporine Eye Drops in the Treatment of Allergic Conjunctivitis-Associated Dry Eye in Children

Start Date01 Jan 2026

Sponsor / Collaborator

Beijing Children's Hospital.Captital Medical University

100 Clinical Results associated with Olopatadine Hydrochloride

100 Translational Medicine associated with Olopatadine Hydrochloride

100 Patents (Medical) associated with Olopatadine Hydrochloride

612

Literatures (Medical) associated with Olopatadine Hydrochloride

10 Nov 2025·Vestnik otorinolaringologii

Comparative analysis of the effectiveness of treatment for exudative otitis media and eustachitis associated with concomitant allergic rhinitis

Article

Author: Kokorina, V.E. ; Bykov, I.A.

Allergic rhinitis (AR) leads not only to significant nasal obstruction and ocular symptoms but also, by affecting the entire respiratory epithelium, causes combined damage to the Eustachian tube and middle ear, resulting in exudative otitis media (EOM). To evaluate the clinical features of EOM of allergic origin and to compare treatment regimens targeting allergic inflammation — with the goal of restoring Eustachian tube function and middle ear drainage — 329 patients with confirmed allergic rhinitis were examined. Following otorhinolaryngological and audiological evaluations, pathology of the middle ear and Eustachian tube was identified in 51% of cases (168 individuals). Interestingly, 16% of these patients subjectively reported no hearing loss or sensation of ear fullness, despite objective confirmation of pathology. To assess the comparative effectiveness of different AR therapy regimens and their impact on middle ear and Eustachian tube pathology, the 168 affected patients were divided into four parallel groups: Main group (41 patients): treated with a fixed-dose combination of mometasone furoate and olopatadine hydrochloride (Rialtris); Control group 1 (45 patients): received intranasal monotherapy with mometasone furoate; Control group 2 (41 patients): treated with the oral antihistamine levocetirizine; Control group 3 (41 patients): received combination therapy of intranasal mometasone furoate and oral levocetirizine. To monitor the restoration of auditory tube function and middle ear pneumatization, tympanometry and micro-otoscopy were performed on days 1, 7, 14, and 30. All treatment regimens positively influenced Eustachian tube dysfunction. The combination of intranasal mometasone furoate and oral levocetirizine demonstrated superior efficacy, with a statistically significant difference (p=0.01, CO = –33.60; 95% CI –61.05 to –6.15). Due to the accelerated recovery of Eustachian tube function and restoration of its drainage capabilities, the need for invasive middle ear drainage procedures (e.g., shunting, tympanostomy) was eliminated in the group receiving the fixed intranasal combination of mometasone furoate and olopatadine hydrochloride. This fixed-dose combination appears to be the optimal treatment for allergic Eustachian tube dysfunction, owing to its direct endonasal action on the respiratory epithelium at the Eustachian tube, allowing for rapid restoration of middle ear ventilation.

12 Sep 2025·INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis

Review

Author: Xu, Chao ; Tian, Han-Ying ; Li, Yu-Zhen ; Liu, Cheng-Jiang

Introduction: The latest international joint guideline supports the use of second-generation H1 antihistamines (sgAHs) as the first-line treatment for chronic spontaneous urticaria (CSU). Methods: PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials of various types of sgAHs in the treatment of CSU up to March 2025. For efficacy, the primary outcome was the change from baseline in the total symptom score, while the secondary outcomes were pruritus score and wheal score. For safety, the total numbers of all withdrawals due to adverse events and common adverse effects were extracted for each treatment, which included central nervous system side effects and anticholinergic side effects. Results: We identified and included 24 randomized clinical trials (RCTs) involving 5,172 patients. Ebastine ranked first in the total symptom score (standardized mean difference [SMD)\ −2.80 [95% confidence interval (CI):−5.12 to −0.47]) and pruritus score (SMD −1.10 [95% CI: −2.06 to −0.13]), while olopatadine ranked first in the wheal score (SMD −0.84 [95% CI: −1.37 to −0.32]). Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio 0.15 [95% CI: 0.03–0.69]) than other sgAHs. Conclusion: Both ebastine and olopatadine showed promising efficacy, and no significant differences were found in acceptability and safety compared with placebo. There are no meaningful differences in safety risks between different second-generation antihistamines.

01 Sep 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database

Article

Author: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Hu, Jiaoyue ; Sun, Le ; Guan, Wen-Ying ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu

BACKGROUND:

Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.

METHODS:

We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.

RESULTS:

Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.

CONCLUSION:

Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.

News (Medical) associated with Olopatadine Hydrochloride

05 May 2026

·www.businesswire.com

BlinkRx Announces Availability of RYALTRIS ® for Convenient Home Delivery Following Glenmark’s Commercial Transition

NEW YORK--(BUSINESS WIRE)--BlinkRx, the digital pharmacy platform designed to make prescription medications more accessible and affordable, today announced that RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray, is now available for fulfillment through the BlinkRx platform. This follows Glenmark Pharmaceuticals Inc., USA’s transition to direct commercialization and distribution of the product. Patients can now access RYALTRIS® through BlinkRx’s streamlined digital platform as allergy season peaks nationwide. As seasonal allergies reach peak levels in many parts of the country, BlinkRx is helping ensure that patients across the United States can access RYALTRIS® quickly and conveniently. While RYALTRIS® is not available through traditional retail pharmacy channels, patients can benefit from a seamless, end-to-end experience through BlinkRx that includes the best available price and free home delivery. “At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. We’re excited to be expanding availability of RYALTRIS® on our platform during the worst seasonal allergies in many parts of the country,” said Geoff Chaiken, co-founder and CEO of BlinkRx. “We are pleased to expand access to RYALTRIS® through BlinkRx, which offers a convenient option for patients,” said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals Inc., USA. “As we continue to advance our direct commercialization efforts in the U.S., partnerships like these play a key role in improving how patients access and experience care.” RYALTRIS® is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.1 It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. With demand for allergy relief increasing during the spring season, ensuring reliable and convenient access to effective therapies remains a priority for both providers and patients. Patients interested in finding out if RYALTRIS® is right for them should speak with their healthcare provider to learn more. Patients with existing RYALTRIS® prescriptions can ask their pharmacist to transfer the prescription to BlinkRx. About BlinkRx BlinkRx is redefining the pharmacy experience with integrated data-driven technology that improves patient access to branded medications. Its prescription journey management platform streamlines every step of the process, improving the prescription journey across all stakeholders. Patients enjoy the lowest network price, free home delivery, and personalized support. Healthcare providers benefit from dedicated access teams and enhanced prior authorization support for their patients. Pharmacies are able to access technologies that improve their ability to serve patients. And pharmaceutical manufacturers gain greater transparency from prescription to fulfillment. Learn more at www.blinkrx.com. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led, pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com *Calculated on the anhydrous basis 1RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland. Please click here to view full prescribing information, including Important Safety Information. For additional information about RYALTRIS® and how to access, please visit us.ryaltris.com. RYALTRIS is a registered trademark of Glenmark Specialty SA.

01 Apr 2026

·www.prnewswire.com

Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio

RYALTRIS® is Glenmark's first innovative product introduced into the U.S. market ELMWOOD PARK, N.J., April 1, 2026 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray in the United States, effective April 1, 2026. This marks a meaningful step in Glenmark's continued expansion in the region with a sustainable approach to building a strong, direct commercial U.S. based presence. RYALTRIS® was launched in the United States in 2022 and is approved by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of symptoms associated with Seasonal Allergic Rhinitis (SAR) in adults and paediatric patients 12 years of age and older1. It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. The product is supplied as a 240-metered spray nasal suspension. Seasonal Allergic Rhinitis affects millions of patients across the United States and remains an area where symptom control and treatment adherence continue to be important considerations. By combining two established therapies in one formulation, RYALTRIS® offers a convenient treatment option1 aligned with evolving patient and physician preferences. Glenmark will directly lead brand strategy, market access, and customer engagement for RYALTRIS® in the U.S. This allows for more focused execution, closer alignment with healthcare providers and greater responsiveness to market needs. Commenting on the development, Marc Kikuchi, President & Business Head, North America said, "The commercialization by Glenmark for RYALTRIS® in the United States is an important step forward for the growth of our company. It allows us greater operational direction in how we engage the market and support healthcare providers and patients across the nation. Today's announcement also marks a significant moment in our broader effort to strengthen our innovative businesses in the U.S. and build a more direct, sustainable commercial presence over time." RYALTRIS® is already approved in key markets including the United States, European Union, United Kingdom, Australia, South Korea, Russia and China. In FY26, RYALTRIS® was launched in 11 additional markets, expanding its presence to 55 countries worldwide. *Calculated on the anhydrous basis 1RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland. Please click here to view full prescribing information, including Important Safety Information. For additional information about RYALTRIS® and how to access, please visit us.ryaltris.com. RYALTRIS is a registered trademark of Glenmark Specialty SA. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit . Logo: SOURCE Glenmark Pharmaceuticals 21% more press release views with Request a Demo

Drug Approval

14 Jan 2026

·www.businesswire.com

Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday ® Once Daily Relief, in the U.S.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday® Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an Antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander. “This launch adds to our current portfolio in the OTC eye-care space which includes Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% strengths,” explains Milan Kalawadia, CEO, North America Generics, Dr. Reddy’s Laboratories, Inc. “The first-to-market launch is a testament to our deep capabilities in bringing store-brand equivalents of OTC brands in the U.S. market. We are excited to deepen our collaboration with our retail customers through this important addition to our store-brand portfolio.” The Pataday® brand had U.S. sales of approximately $69.9 million for the latest 52 weeks period ending December 27, 2025, according to NIQ data.* Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is available in a 2.5 mL bottle. Pataday is a registered trademark of Novartis AG. *NielsenIQ Retail Measurement, xAOC, data through December 2025 RDY-0126-OTC About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.

Drug Approval

100 Deals associated with Olopatadine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01192	Olopatadine Hydrochloride	R01AC08 S01GX09	DB00768

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	United States	Novartis Pharmaceuticals Corp.	15 Apr 2008
Allergic rhinoconjunctivitis	Japan	Novartis Pharma KK	26 Jul 2006
Seasonal allergic conjunctivitis	European Union	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Iceland	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Liechtenstein	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Norway	Novartis Europharm Ltd.	16 May 2002
Pruritus	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Rhinitis, Allergic	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Urticaria	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Conjunctivitis, Allergic	United States	Alcon Laboratories, Inc.	18 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Perennial allergic conjunctivitis	Phase 3	-	Alcon Research Ltd.	01 Jan 2012
Acute conjunctivitis	Phase 3	-	Alcon Research Ltd.	01 Oct 2009
Rhinitis, Allergic, Perennial	Phase 3	United States	Alcon Research Ltd.	01 Dec 2006
Rhinoconjunctivitis	Phase 3	-	Alcon Research Ltd.	18 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


APAO2019	Not Applicable	Vernal Keratoconjunctivitis	96	Olopatadine 0.1%	csvcxvvtrx(lerxcvmqdi) = rqvwtpvihm qkdajmpqmf (cztdltjvoq )	Positive	06 Mar 2019
				Sodium Cromoglycate 2%	csvcxvvtrx(lerxcvmqdi) = lubpqsphrl qkdajmpqmf (cztdltjvoq )
AAAAI2019	Not Applicable	Rhinitis, Allergic, Seasonal	-	GSP301 (olopatadine 665μg/mometasone 25μg BID)	gppmeapavw(eqztcjaoor) = uwchsprcih uoxeftbbml (uobitdonkx, -0.41 to -0.05)	-	01 Feb 2019
NCT00609128 (CTgov)	Not Applicable	Conjunctivitis, Allergic \| Lacerations	21	olopatadine	jzaispjngs(gzlbrlneiy) = gpryidptzx mtqbyhbxsg (qouomqmdqw, fffcztbuyu - ycxfshznhi) View more	-	20 Sep 2018
AAAAI2018	Not Applicable	Rhinitis, Allergic, Seasonal	-	GSP301 (olopatadine 665μg/mometasone 25μg BID)	qvrqsizbkz(twqcbdxafn) = jmzroiukkk rbnenvdypi (fzxzmbcehw, -0.35[-0.63 - -0.07])	-	01 Feb 2018
ARVO2015	Phase 3	-	448	Olopatadine 0.77%	uclnuvfoah(mklqowteeo) = aajvckjipm cntqdnkktq (ilfriuybec )	Positive	01 Jun 2015
				Olopatadine 0.1%	uclnuvfoah(mklqowteeo) = eyyoesqomv cntqdnkktq (ilfriuybec )
NCT01697969 (CTgov)	Phase 4	Conjunctivitis, Allergic	17	Olopatadine hydrochloride (Left Eye)	varsvxygwl(xbeajztsyo) = uwycvhdbwe lrkleqnrsm (nceuxyvgoa, 0.85) View more	-	18 Aug 2014
				Olopatadine hydrochloride (Right Eye)	varsvxygwl(xbeajztsyo) = rvxmemlueg lrkleqnrsm (nceuxyvgoa, 0.92) View more
NCT01743027 (CTgov)	Phase 3	Conjunctivitis, Allergic \| Perennial allergic conjunctivitis	902	AL-4943A ophthalmic solution (AL-4943A)	qgzklnimzs(vjouciawqa) = gcjlwrptml kcyvvlckno (fngjygxytz, 0.069) View more	-	11 Aug 2014
				Olopatadine hydrochloride ophthalmic solution, 0.2% (PATADAY)	qgzklnimzs(vjouciawqa) = evkfaitaak kcyvvlckno (fngjygxytz, 0.069) View more
NCT01698814 (CTgov)	Phase 3	Conjunctivitis, Allergic	518	AL-4943A Ophthalmic Solution (AL-4943A)	ylhnskihdm = cgtczdtusm bqxabruqaw (mfnefjymmw, kfbkieqfkt - uqypcpmojq) View more	-	28 Feb 2014
				AL-4943A Ophthalmic Solution (AL-4943A Vehicle)	ylhnskihdm = yrliivagyn bqxabruqaw (mfnefjymmw, thdmxlhjrh - xzimknxefz) View more
NCT01732757 (CTgov)	Phase 4	Acute conjunctivitis \| Conjunctivitis, Allergic	157	Alcaftadine 0.25% (Lastacaft®)	arybxtvgmz(kdxkxpfgtj) = cmuhyhcdwe gidomzaopv (lvienmnddb, 0.582) View more	-	14 Jan 2014
				Olopatadine 0.2% (Pataday™)	arybxtvgmz(kdxkxpfgtj) = wvplcsdejh gidomzaopv (lvienmnddb, 0.752) View more
NCT01007253 (CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	21	PL (PL/PL)	uzxpecjiwx(tlldzeppni) = icnejrjjhk rweiuqxwjk (brzhublwsq, yatbncxmsj - rwyrsvzpfb) View more	-	17 Jul 2013
				fluticasone furoate (FF)+PL (FF/PL)	uzxpecjiwx(tlldzeppni) = oqjtcqdpzj rweiuqxwjk (brzhublwsq, cczscvquwk - cslzgldmpr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis